FINWIRES · TerminalLIVE
FINWIRES

美伊停火前景不明朗,分析家對違反停火協議的報導保持謹慎

-- 儘管美伊停火兩週的消息已引起市場歡呼,但分析師對停火的持久性提出質疑,因為已有違反停火協議的事件頻頻登上新聞頭條。 週三,全球股市上漲,油價跌破每桶100美元,此前華盛頓和德黑蘭達成協議,暫停了蔓延至整個中東地區的軍事衝突。 川普曾在週二設定美東時間晚上8點為伊朗全面重新開放霍爾木茲海峽的最後期限,但應巴基斯坦的要求,他同意暫停對伊朗的攻擊計畫兩週。德黑蘭表示,將在與伊朗當局協調的前提下,允許「安全通行」這項關鍵貿易通道。 史蒂費爾首席經濟學家林賽·皮格扎在一份報告中表示:“儘管市場對該協議表示歡迎,但停火能否持續,以及霍爾木茲海峽的交通能否恢復,仍有待觀察。” 有關停火協議遭到破壞的報道令投資人憂心忡忡,也顯示協議可能十分脆弱。 根據美國有線電視新聞網(CNN)引述半官方通訊社法爾斯通訊社報道,以色列襲擊黎巴嫩後,伊朗暫停了油輪通過該水道的通行。另據報道,科威特和阿聯酋稱遭到伊朗無人機和飛彈攻擊。 巴基斯坦總理謝赫巴茲·謝里夫曾與陸軍元帥阿西姆·穆尼爾共同斡旋達成停火協議。他在X網站上發文稱,違反停火協議「破壞了和平進程的精神」。 星展銀行能源、可再生能源和基礎設施研究主管蘇夫羅·薩卡爾表示:「停火協議有效地阻止了即將發生的大規模襲擊,並為談判創造了空間,但它並不能解決根本衝突或基礎設施受損的問題。兩週的時間非常短暫,供應鏈的結構性破壞是深遠的。」 根據媒體報導,焦點轉向伊朗向美國提出的十點方案,其中包括解除對伊朗的製裁、承認伊朗的鈾濃縮計劃以及繼續控制霍爾木茲海峽。 「如果這真的是談判的基礎,那麼談判可能會很艱難,因為其中一些條款,特別是對海峽的控制權,很可能令地區大國難以接受,而且據報道伊朗仍然打算對過境收取通行費,」都鐸·皮克林·霍爾特公司分析師馬特·波蒂略在發給的一份報告中寫道。

Related Articles

Asia

Fadu Returns to Profit in Q1 as Sales Triple; Shares Jump 14%

Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.

$KOSDAQ:440110
Asia

ASX Biggest Losers

Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07

$^AXJO$ASX:COH$ASX:EVT$ASX:NXG$ASX:ORG$ASX:PDN$ASX:RHC$ASX:SX2$ASX:TLX$ASX:TUA$ASX:WTC
Asia

Sun Pharmaceutical to Acquire US-Based Organon in $11.8 Billion Deal

Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.

$BOM:524715$NSE:SUNPHARMA